Free Trial

Standard BioTools (LAB) Stock Price, News & Analysis

+0.02 (+0.77%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.33 million shs
Average Volume
2.29 million shs
Market Capitalization
$757.21 million
P/E Ratio
Dividend Yield
Price Target

Standard BioTools MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
37.3% Upside
$3.58 Price Target
Short Interest
3.09% of Float Sold Short
Dividend Strength
News Sentiment
1.32mentions of Standard BioTools in the last 14 days
Based on 15 Articles This Week
Insider Trading
Acquiring Shares
$3.47 M Bought Last Quarter
Proj. Earnings Growth
From ($0.40) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

328th out of 916 stocks

Analytical Instruments Industry

10th out of 28 stocks

LAB stock logo

About Standard BioTools Stock (NASDAQ:LAB)

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

LAB Stock Price History

LAB Stock News Headlines

See More Headlines
Receive LAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$106.34 million
Book Value
$1.99 per share


Free Float
Market Cap
$774.62 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

LAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Standard BioTools stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LAB shares.
View LAB analyst ratings
or view top-rated stocks.

What is Standard BioTools' stock price target for 2024?

3 brokerages have issued twelve-month target prices for Standard BioTools' shares. Their LAB share price targets range from $3.25 to $4.00. On average, they anticipate the company's share price to reach $3.58 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts price targets for LAB
or view top-rated stocks among Wall Street analysts.

How have LAB shares performed in 2024?

Standard BioTools' stock was trading at $2.21 on January 1st, 2024. Since then, LAB shares have increased by 18.1% and is now trading at $2.61.
View the best growth stocks for 2024 here

When is Standard BioTools' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our LAB earnings forecast

How were Standard BioTools' earnings last quarter?

Standard BioTools Inc. (NASDAQ:LAB) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.05. The firm had revenue of $28.19 million for the quarter, compared to the consensus estimate of $28 million. Standard BioTools had a negative net margin of 70.98% and a negative trailing twelve-month return on equity of 144.74%.

What ETFs hold Standard BioTools' stock?

ETFs with the largest weight of Standard BioTools (NASDAQ:LAB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What guidance has Standard BioTools issued on next quarter's earnings?

Standard BioTools updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$205.0 million.

Who are Standard BioTools' major shareholders?

Standard BioTools' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.49%), Sumitomo Mitsui Trust Holdings Inc. (3.05%), Nikko Asset Management Americas Inc. (3.05%), Nan Fung Group Holdings Ltd (0.65%), Magnetar Financial LLC (0.52%) and Gagnon Securities LLC (0.29%). Insiders that own company stock include Caligan Partners Lp, Casdin Partners Master Fund, L, Eli Casdin and Jeffrey G Black.
View institutional ownership trends

How do I buy shares of Standard BioTools?

Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LAB) was last updated on 5/23/2024 by Staff

From Our Partners